Mechanistic Links Between Gut Dysbiosis, Insulin Resistance, and Autism Spectrum Disorder.

This review looks at how gut bacteria problems might connect autism and blood sugar issues. When gut bacteria are out of balance, it can cause inflammation and affect how the brain develops. Children with autism often have different gut bacteria - more harmful types and fewer helpful ones. The researchers suggest that fixing gut bacteria through diet changes or treatments might help with both autism symptoms and metabolism problems.

This review examines the complex relationships between gut microbiome disruption (dysbiosis), insulin resistance, and autism spectrum disorder through the gut-brain-metabolic axis. The authors explore molecular mechanisms including immune pathway activation (TLR/NF-κB), metabolic signaling disruption (PI3K/Akt/mTOR), and the role of microbial metabolites like short-chain fatty acids and GABA. Common microbial changes in both ASD and insulin resistance include increased harmful bacteria (Clostridium, Desulfovibrio) and reduced beneficial bacteria (Bifidobacterium, butyrate-producers). The review suggests these changes contribute to intestinal barrier dysfunction, systemic inflammation, and altered brain development, proposing potential therapeutic approaches including microbiota modulation, IGF-1 treatment, and dietary interventions for addressing metabolic comorbidities in autism.

Understanding gut-brain-metabolic connections may inform development of microbiota-targeted therapies for autistic individuals with metabolic comorbidities. Potential interventions include dietary modifications, probiotic supplementation, and IGF-1 treatment, though clinical evidence for these approaches remains limited and requires further research.

As a narrative review, findings depend on quality and selection of included studies. No systematic methodology reported. Mechanistic pathways remain largely theoretical. Clinical translation of proposed therapeutic strategies requires further validation through controlled trials.

Autism spectrum disorder (ASD) is a neurodevelopmental condition frequently associated with gastrointestinal symptoms, gut dysbiosis, and metabolic dysfunctions such as insulin resistance (IR). Recent evidence suggests that the gut microbiota may influence both metabolic and neurological processes through the gut-brain-metabolic axis. This review explores the molecular mechanisms linking dysbiosis, IR, and ASD, focusing on pathways such as TLR/NF-κB activation, PI3K/Akt/mTOR disruption, and the action of microbial metabolites, like short-chain fatty acids (SCFAs), lipopolysaccharide (LPS), and γ-aminobutyric acid (GABA). We discuss how dysbiosis may contribute to increased intestinal permeability, systemic inflammation, and neuroimmune activation, ultimately affecting brain development and behavior.

Common microbial alterations in ASD and IR-including increased Clostridium, Desulfovibrio, and Alistipes, and reduced Bifidobacterium and butyrate-producing genera-suggest a shared pathophysiology. We also highlight potential therapeutic strategies, such as microbiota modulation, insulin-like growth factor 1 (IGF-1) treatment, and dietary interventions. Understanding these interconnected mechanisms may support the development of microbiota-targeted approaches for individuals with ASD metabolic comorbidities.